Covaxin phase 3 data shows 77.8% efficacy: Lancet

A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.

from Times of India https://ift.tt/30aDSMa
https://ift.tt/eA8V8J November 12, 2021 at 02:01AM

Comments

Popular posts from this blog

Covid live: Record 50,000+ infections on Sunday

Impact of pandemic? Women jobseekers fell by 34% in 2021

SC slams trial courts for seeking needless custody